全球镰状细胞疾病（SCD）治疗市场规模、份额、趋势和成长分析报告：2026-2034年

预计镰状细胞疾病 (SCD) 治疗市场规模将从 2025 年的 46.5 亿美元增长到 2034 年的 224.8 亿美元，2026 年至 2034 年的复合年增长率为 19.12%。

由于全球对镰状细胞疾病 (SCD) 的认识不断提高以及诊断率的提升，SCD 治疗市场正在不断扩大。传统的治疗方法主要包括止痛和输血，而如今，治疗方法已发展到包括使用缓解疾病药物和先进的生物製药。研发投入的增加以及孤儿药的优先资助正在加速创新，尤其是在基因治疗和根治性疗法领域。

关键成长要素包括特定地区发病率上升、新生儿筛检计画改善以及针对罕见疾病的有利法规结构。基因编辑技术和造血干细胞移植的进步正在开闢新的治疗途径。製药公司正投资研发标靶治疗减轻闭塞性疾病危机并提高患者的生活品质。

基因疗法商业化带来的治癒性治疗潜力使其未来前景十分光明。然而，高昂的治疗费用和医疗资源分配不均可能阻碍其广泛应用。为了在未来几年实现持续成长，新兴市场医疗基础设施的扩建和医保报销的加强至关重要。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球镰状细胞疾病（SCD）治疗市场：依药物类别划分

• 市场分析、洞察与预测
• 抗代谢药物
• 胺基酸
• NSAIDs
• 单株抗体
• 其他（止痛药、退烧药等）

第五章 全球镰状细胞疾病（SCD）治疗市场：依疾病类型划分

• 市场分析、洞察与预测
• 血红素SS（HbSS）
• SC血红素（HbSC）
• β-地中海型贫血血红蛋白（HbS）

第六章 全球镰状细胞疾病（SCD）治疗市场：依年龄层划分

• 市场分析、洞察与预测
• 孩子
• 成人

第七章 全球镰状细胞疾病（SCD）治疗市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 肠外

第八章 全球镰状细胞疾病 (SCD) 治疗市场：依分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第九章 全球镰状细胞疾病（SCD）治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Novartis AG
  • Pfizer Inc
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics
  • Emmaus MedicalInc
  • Bluebird BioInc
  • Hoffmann-La Roche Ltd
  • Vertex Pharmaceuticals Incorporated
  • Agios PharmaceuticalsInc
  • GlycoMimetics
  • Graphite BioInc
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd
  • AstraZeneca
  • Hikma Pharmaceuticals PLC

The Sickle Cell Disease Treatment Market size is expected to reach USD 22.48 Billion in 2034 from USD 4.65 Billion (2025) growing at a CAGR of 19.12% during 2026-2034.

The sickle cell disease (SCD) treatment market has expanded as awareness and diagnosis rates improve globally. Traditionally managed with pain-relief therapies and blood transfusions, treatment approaches have evolved to include disease-modifying drugs and advanced biologics. Increasing research investment and orphan drug incentives have accelerated innovation, particularly in gene therapy and curative approaches.

Major growth drivers include rising prevalence in certain geographic regions, improved newborn screening programs, and supportive regulatory frameworks for rare diseases. Advances in gene-editing technologies and hematopoietic stem cell transplantation have opened new therapeutic possibilities. Pharmaceutical companies are investing in targeted therapies that reduce vaso-occlusive crises and improve patient quality of life.

Future prospects are highly promising with the commercialization of gene therapies offering potential long-term cures. However, high treatment costs and access disparities may challenge widespread adoption. Expanding healthcare infrastructure and reimbursement support in emerging markets will be crucial for sustainable growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Antimetabolites
• AminAcids
• NSAIDs
• Monoclonal Antibodies
• Others (Analgesis and Antipyretics, etc)

By Disease Type

• Hemoglobin S5 (HbSS)
• Hemoglobin SC (HbSC)
• Hemoglobin (HbS) beta thalassemia

By Age-Group

• Children
• Adults

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Novartis AG, Pfizer Inc, BristolMyers Squibb Company, CRISPR Therapeutics, Emmaus Medical, Inc, Bluebird Bio, Inc, HoffmannLa Roche Ltd, Vertex Pharmaceuticals Incorporated, Agios Pharmaceuticals, Inc, GlycoMimetics, Graphite Bio, Inc, Mylan NV, Teva Pharmaceutical Industries Ltd, AstraZeneca, Hikma Pharmaceuticals PLC

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Antimetabolites Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. AminAcids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. NSAIDs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others (Analgesis and Antipyretics, etc) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Hemoglobin S5 (HbSS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hemoglobin SC (HbSC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Hemoglobin (HbS) beta thalassemia Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY AGE-GROUP 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Age-group
• 6.2. Children Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Drug Class
  • 9.2.2 By Disease Type
  • 9.2.3 By Age-group
  • 9.2.4 By Route Of Administration
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Drug Class
  • 9.3.2 By Disease Type
  • 9.3.3 By Age-group
  • 9.3.4 By Route Of Administration
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Drug Class
  • 9.4.2 By Disease Type
  • 9.4.3 By Age-group
  • 9.4.4 By Route Of Administration
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Drug Class
  • 9.5.2 By Disease Type
  • 9.5.3 By Age-group
  • 9.5.4 By Route Of Administration
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Drug Class
  • 9.6.2 By Disease Type
  • 9.6.3 By Age-group
  • 9.6.4 By Route Of Administration
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL SICKLE CELL DISEASE TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Novartis AG
  • 11.2.2 Pfizer Inc
  • 11.2.3 Bristol-Myers Squibb Company
  • 11.2.4 CRISPR Therapeutics
  • 11.2.5 Emmaus MedicalInc
  • 11.2.6 Bluebird BioInc
  • 11.2.7 Hoffmann-La Roche Ltd
  • 11.2.8 Vertex Pharmaceuticals Incorporated
  • 11.2.9 Agios PharmaceuticalsInc
  • 11.2.10 GlycoMimetics
  • 11.2.11 Graphite BioInc
  • 11.2.12 Mylan N.V
  • 11.2.13 Teva Pharmaceutical Industries Ltd
  • 11.2.14 AstraZeneca
  • 11.2.15 Hikma Pharmaceuticals PLC